J2kbio KRX:420570KOSDAQ
제이투케이바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days7
DART filings, 7 days0
Articles tracked11since Sep 11
In Q2 2026, J2kbio reported revenue of ₩15.6bn, up 83.0% year on year, and operating profit of ₩2.7bn. J2kbio (제이투케이바이오) appeared in 7 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 28 with 7 articles. The most common catalyst was policy & overseas (1).
J2kbio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩15.6bn | +83.0% | ₩2.7bn margin 17.3% | ₩2.7bn |
| Q1 2026 | ₩11.1bn | +53.1% | ₩1.9bn margin 17.2% | ₩1.6bn |
| Q4 2025 derived | ₩8.6bn | +27.2% | ₩643m margin 7.5% | ₩715m |
| Q3 2025 | ₩8.6bn | +31.5% | ₩1.2bn margin 14.6% | ₩838m |
| Q2 2025 | ₩8.5bn | -29.2% | ₩698m margin 8.2% | ₩883m |
| Q1 2025 | ₩7.3bn | -6.9% | ₩332m margin 4.6% | ₩239m |
| Q4 2024 derived | ₩6.8bn | -18.9% | ₩11m margin 0.2% | ₩289m |
| Q3 2024 | ₩6.5bn | -15.7% | −₩133m margin −2.0% | −₩250m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
J2kbio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest J2kbio news Korean headlines
-
제이투케이바이오, 美 카사바파마와 한국 대리점 계약
3 more on this story · 3 outlets
- 제이투케이바이오, 美 카사바파마와 한국 대리점 계약서울경제 · Oct 28 14:50
- 제이투케이바이오, 美 카사바파마와 한국 대리점 계약더바이오 · Oct 28 15:19
- 제이투케이바이오, 美 카사바파마와 한국 대리점 계약 및 유통망 MOU 체결스페셜타임스 · Oct 28 20:26